Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Hepregen Corporation and The Hamner Institutes for Health Sciences Announce Research Partnership

Published: Tuesday, August 13, 2013
Last Updated: Tuesday, August 13, 2013
Bookmark and Share
Agreement provides opportunity to collaborate on research supporting next generation in vitro micro-liver analysis associated with pharmaceutical and chemical product development.

Hepregen Corporation and The Hamner Institutes for Health Sciences announced execution of an agreement that provides for a research partnership between the two entities. The research effort will be led by Dr. Edward LeCluyse, Associate Investigator at The Hamner, and Dr. Michael Holsapple, newly appointed Vice President of Toxicology Product Development at Hepregen, along with Mr. Jack McGeehan, Hepregen’s Vice President of Operations. The partnership will focus on research and development efforts aimed at defining: (1) basic concepts regarding the potential for new micro-liver products and (2) new applications and assay methodologies for Hepregen’s existing micro-liver products that are already transforming pharmaceutical product development.

“This Hamner-Hepregen partnership brings together outstanding teams of scientists from both organizations, creating a cooperative effort that will yield new knowledge about how best to utilize Hepregen’s micro-liver products for safety testing associated with pharmaceutical and chemical product development,” stated Dr. Vincent Zurawski, Hepregen’s chief executive officer.

Dr. William Greenlee, President and CEO of The Hamner also commented, “This research partnership provides yet another example of The Hamner’s ability to attract and partner with high quality commercial enterprises that share our organization’s commitment to advancing human health. We look forward to working with Hepregen in our mutual quest to provide advanced, next generation predictive health tools to the pharmaceutical, chemical and related industries.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

QPS Holdings and Hepregen Corporation Announce Commercial Partnership
The agreement provides co-promotion, marketing and sales of services utilizing Hepregen’s proprietary HepatoPac products.
Thursday, May 30, 2013
Hepregen Announces Issuance of its First Patent
The patent protects manufacturing methods of Hepatopac and related products.
Tuesday, May 28, 2013
Scientific News
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Novel Technique for Kidney Research Developed
To better understand how the treatment leads to kidney damage, and possibly prevent it, a team of researchers at Yale School of Medicine developed a new 3D-imaging technique to peer deep into these vital organs.
Microscopic Fish are 3D-Printed to do More Than Swim
Researchers demonstrate a novel method to build microscopic robots with complex shapes and functionalities.
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
A Better Way to Personalize Bladder Cancer Treatments
Researchers at UC Davis, in collaboration with colleagues at Jackson Laboratory, have developed a new way to personalize treatments for aggressive bladder cancer.
Breath of Fresh Air for Asthmatics
Researchers hope to develop a platform that will allow a range of drugs to be delivered by inhalation.
Capturing Cell Growth in 3-D
Spinout’s microfluidics device better models how cancer and other cells interact in the body.
Elastic Patch Releases Drugs in a Stretch
Researchers from have developed a drug delivery technology that consists of an elastic patch that can be applied to the skin and will release drugs whenever the patch is stretched.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Liposomes: A Basis for Drugs of the Future
An international group of scientists have recently presented a review of liposomes, microscopic capsules widely used all over the world in the development of new drugs.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!